Squalamine
OTHER NAME(S): 3-({3-[(4-Aminobutyl)amino]propyl}amino)-7-hydroxycholestan-24-yl Hydrogen Sulfate, Squalamine, Escualamina
Overview
Squalamine is a chemical found in the stomach and liver of the spiny dogfish shark. Squalamine can also be made in the lab.
Squalamine is a chemical called an aminosterol. It has effects that might prevent bacteria from growing and causing infections. It also might prevent the growth of tumors.
People use squalamine for age-related vision loss, lung cancer, ringworm, and many other conditions, but there is no good scientific evidence to support these uses.
Don't confuse squalamine with shark cartilage or shark liver oil. These contain squalamine but they are not the same.
Uses
We currently have no information for Squalamine overview.
Side Effects
When taken by mouth: There isn't enough reliable information to know if squalamine is safe or what the side effects might be.
When applied into the eye: Squalamine eye drops are possibly safe when used twice daily for up to 38 weeks. It seems to be well-tolerated.
Precautions
When taken by mouth: There isn't enough reliable information to know if squalamine is safe or what the side effects might be.
When applied into the eye: Squalamine eye drops are possibly safe when used twice daily for up to 38 weeks. It seems to be well-tolerated.
Pregnancy and breast-feeding: There isn't enough reliable information to know if squalamine is safe when used while pregnant or breast-feeding. Stay on the safe side and avoid use.
Children: Squalamine is possibly safe in children 6-15 years-old when applied to the scalp in a lotion once daily for up to 3 weeks.
Interactions
We currently have no information for Squalamine overview.
Dosing
There isn't enough reliable information to know what an appropriate dose of squalamine might be. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult a healthcare professional before using.
References
- Magainin Pharmaceuticals announces new research program for anti-angiogenesis agent - Squalamine - at Georgetown Univ Med Ctr. PRNewswire. http://www.prnewswire.com (Accessed 22 January 2000).
- Sills AK Jr, Williams JI, Tyler BM, et al. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature. Cancer Res 1998;58:2784-92.
- Kikuchi K, Bernard EM, Sadownik A, et al. Antimicrobial activities of squalamine mimics. Antimicrob Agents Chemother 1997;41:1433-8.
- Moore KS, Wehrli S, Roder H, et al. Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci U S A 1993;90:1354-8.
- Magainin Presents Neuroblastoma Data for Squalamine at AACR Meeting. Available at: http://www.prnewswire.com (Accessed 3 April 2000).
- Bhargava P, Marshall JL, Dahut W, et al. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers. Clin Cancer Res. 2001;7(12):3912-9.
- Coulibaly O, Thera MA, Koné AK, et al. A double-blind randomized placebo-controlled clinical trial of squalamine ointment for tinea capitis treatment. Mycopathologia. 2015;179(3-4):187-93.
- Garcia CA, Quiroz-Mercado H, Uwaydat S, et al. A phase I/II trial of intravenous squalamine lactate for treatment of choroidal neovascularization in age related macular degeneration (ARMD). Invest. Ophthal. Visual Sci. 2004;45(13):2362.
- Rose V, Schiller J, Wood A, et al. Randomized phase II trial of weekly squalamine, carboplatin, and paclitaxel as first line therapy for advanced non-small cell lung cancer. J. Clin. Oncol. 2004;22(14 suppl):7109.
- Wroblewski JJ, Hu AY. Topical squalamine 0.2% and intravitreal ranibizumab 0.5 mg as combination therapy for macular edema due to branch and central retinal vein occlusion: An open-label, randomized study. Ophthalmic Surg Lasers Imaging Retina. 2016;47(10):914-923.
- Herbst RS, Hammond LA, Carbone DP, et al. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2003;9(11):4108-15.